Clinical Trials Logo

Multiple System Atrophy (MSA) clinical trials

View clinical trials related to Multiple System Atrophy (MSA).

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05923866 Recruiting - Clinical trials for Multiple System Atrophy (MSA)

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Start date: September 22, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

NCT ID: NCT03811808 Recruiting - Clinical trials for Multiple System Atrophy (MSA)

Multiple System Atrophy Multidisciplinary Clinic

Start date: March 2016
Phase:
Study type: Observational

This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden. Data will be collected through valid rating scales completed by patients and caregivers at home or in the MSA clinic.

NCT ID: NCT02778607 Recruiting - Clinical trials for Corticobasal Degeneration

PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK

PROSPECT-M
Start date: October 2014
Phase:
Study type: Observational [Patient Registry]

Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments. To aid the development of new treatment trials, there is a pressing need to develop better methods for diagnosing these conditions early, and to track disease progression. The PROSPECT-M-UK study will collect standardised clinical data over time. Patients will also have the option to have a brain MRI scan, eye movement exam and donate blood, skin and spinal fluid samples, with the aim to identify "biomarkers" that can improve the accuracy of early diagnosis and track the natural time course of disease. Control participants and those not meeting criteria for Parkinson's disease or other defined conditions but are considered by the investigator group to be allied syndromes or at risk states (atypical parkinsonian syndromes), will also be examined. Patients can also participate via the CBD European registry or in a one-off study assessment through the cross-sectional study, which involves completing questionnaires and a blood sample donation.